Mereo BioPharma(MREO) - 2023 Q4 - Annual Results

Exhibit 99.1 Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update — Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively Partnering discussions for alvelestat progressing with plans to initiate Phase 3 with a partner around the end of 2024 Cash of $57.4 million as of December 31, 2023 expected to fund operations into 2026 2023 Highli ...